AI Hallucinations: What Are They and Are They Always Bad?
AI hallucinations may not always be bad, according to a panel of experts at the…
AI Hallucinations: What Are They and Are They Always Bad?
AI hallucinations may not always be bad, according to a panel of experts at the MedCity INVEST Digital Health conference. Instead, they may let people know when there are gaps in the data. The post AI Hallucinations: What Are They and Are They Always Bad? appeared first on MedCity News.
Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
Pfizer is acquiring Metsera and its pipeline of obesity medications that could offer dosing and tolerability advantages for patients as well as a manufacturing edge for the pharma giant. Key data Phase 2 readouts for Metsera’s lead GLP-1 drug candidate are expected in 2026. The post Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major…
Pharmacogenomics Can Help Buffer Female Cardiac Patients From Impacts Of Funding Cuts
Pharmacogenomics offers an opportunity to help shield female cardiology patients from some of the negative impacts by helping to streamline the process from diagnosis to finding a successful treatment for that patient. The post Pharmacogenomics Can Help Buffer Female Cardiac Patients From Impacts Of Funding Cuts appeared first on MedCity News.
5 Key Facts About Medicaid Coverage for People With Intellectual and Developmental Disabilities (I/DD)
Among the estimated 8 million people with intellectual and developmental disabilities (I/DD), over three million have Medicaid coverage.
Treating Uncertainty: How Successful Pharma Leaders Can Protect Employee Wellbeing and the Bottom Line
With employee anxiety at an all-time high, reducing fear and stress is increasingly important to organizational performance. While leaders cannot control external events, they can help mitigate their impacts on their organizations and people. The post Treating Uncertainty: How Successful Pharma Leaders Can Protect Employee Wellbeing and the Bottom Line appeared first on MedCity News.
The Impact of H.R. 1 on Two Medicaid Eligibility Rules
This issue brief describes the impact of H.R.1’s 10-year delay in implementing provisions in two Medicaid eligibility rules that would have reduced red tape. The delayed rules are projected to decrease federal spending and future Medicaid and CHIP enrollment and increase coverage loss.
States Are Cutting Medicaid Provider Payments Long Before Trump Cuts Hit
Every day for nearly 18 years, Alessandra Fabrello has been a medical caregiver for her son, on top of being his mom. “It is almost impossible to explain what it takes to keep a child alive who should be dead,” said Fabrello, whose son, Ysadore Maklakoff, experienced a rare brain condition called acute necrotizing encephalopathy…
Seven Starling Raises $8M to Expand Access to Maternal Mental Health Support
Seven Starling’s $8 million raise was led by Rethink Impact and included participation from Pear VC, Zeal Capital Partners, Magnify Ventures, Ulu Ventures, Expa, Fiore Ventures, the March of Dimes, Rogue Women’s Fund and Graham & Walker. The post Seven Starling Raises $8M to Expand Access to Maternal Mental Health Support appeared first on MedCity…
Agentic AI Could Push Healthcare Into a Legal Gray Area, Attorney Says
Agentic AI is starting to make a splash in the healthcare world, but one attorney warns that it could also push the industry into a gray area of liability and patient safety. Without strong guardrails, errors could have life-or-death consequences, said Lily Li, founder of law firm Metaverse Law. The post Agentic AI Could Push…
Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval
Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda. The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins…
